Advanced Eye Research Associates — research payments reported

By program year

4 rows

Year	Kind	Amount	Payments
2025	Research	$6,667	1
2022	Research	$106,305	5
2021	Research	$10,123	3
2020	Research	$2,500	1

Breakdown

Who paid Research payments · program years 2020–2025

AbbVie, Inc. $111,903 5 payments
Aerie Pharmaceuticals, Inc. $12,623 4 payments
Alcon Research LLC $1,069 1 payment

Studies the money was for Research payments · program years 2020–2025

The Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator is used to deliver an implant with medicine to the eye. AbbVie is updating the DEX PS DDS Applicator. This purpose of this study is to show that the updated DEX PS DDS Applicator works in adult participants with macular edema due to retinal diseases. $75,681 2 payments
A Study to Evaluate an Updated Dexamethasone Intravitreal (Into the Eye) Applicator in Adult Participants With Macular Edema Due to Diseases of the Retina $29,555 2 payments
A Phase 2 Study Evaluating the Safety and Efficacy of Netarsudil Ophthalmic Solution in Patients With Corneal Edema Due to Fuchs Corneal Dystrophy (Fuchs) $12,623 4 payments
Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of ABBV-6628 in Subjects with Geographic Atrophy Secondary to Age-Related Macular Degeneration $6,667 1 payment
A Phase 2 Study Evaluating the Safety and Efficacy of Netarsudil Ophthalmic Solution in Patients With Corneal Edema Due to Fuchs Corneal Dystrophy (Fuchs) $1,069 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.